GLP-1 & Weight Loss
Best Compounded Semaglutide Providers of 2026
For clinician-guided compounded semaglutide online, our top pick for 2026 is MEDVi, with Wellorithm, SynergyRX, and TrimRx also standing out…
4.3
Category
GLP-1 & Weight Loss
GLP-1 & Weight Loss
Best GLP-1 Weight-Loss Programs of 2026: 7 Telehealth Services Ranked
GLP-1 telehealth programs make medications like semaglutide and tirzepatide accessible online, without insurance. We evaluated seven leading services
4.6
GLP-1 & Weight Loss
Liv Body Review 2026: I Tried Their GLP-1 Support Stack for 6 Weeks
A hands-on, six-week diary of Liv Body's weight-loss and GLP-1 support supplements — what actually moved the needle, and what…
4.2
GLP-1 & Weight Loss
Telos RX Review 2026: GLP-1 Meets Peptide Therapy — What You’re Actually Getting
Telos RX blends GLP-1 weight loss with peptide prescriptions. We explain what that means, whether it's worth it, and the…
4.2
GLP-1 & Weight Loss
SynergyRX Review 2026: Streamlined GLP-1 Weight Loss, Put to the Test
SynergyRX is a lean, no-frills GLP-1 telehealth service for weight loss. We tested how fast, affordable, and reliable it really…
4.1
GLP-1 & Weight Loss
Wellorithm Review 2026: Can an ‘Algorithm’ Personalize GLP-1 Weight Loss?
Wellorithm promises expert-guided, personalized GLP-1 weight loss. We test whether its data-driven approach actually tailors your plan.
4.2
GLP-1 & Weight Loss
SkinnyRx Review 2026: Affordable GLP-1 Telehealth, Tested
SkinnyRx is a value-focused GLP-1 telehealth program offering compounded semaglutide and tirzepatide at some of the lower price points in…
4.1
GLP-1 & Weight Loss
MEDVi Review 2026: Clinician-Guided GLP-1 Weight Loss, Tested
MEDVi offers clinician-guided GLP-1 weight-loss care via telehealth. We tested the onboarding, provider access, medication, and value.
4.3
GLP-1 & Weight Loss
Sprout Health Review 2026: Compounded vs. Brand-Name GLP-1
Sprout Health is a GLP-1 telehealth program notable for offering both compounded and, where appropriate, brand-name medication options, with guidance…
4.3